Previsioni

Il prezzo obiettivo medio degli analisti è +11,75€ (+51,81%). La mediana è +10,72€ (+38,50%).

Acquista	14
Mantieni	19
Vendi	4

Notizie Vai al feed delle notizie

Bluebird Mining Ventures Ltd schedules annual general meeting for 9 September in St Helier

Bluebird Mining Ventures Ltd has scheduled its annual general meeting for 9 September 2025 in St Helier, Jersey. The agenda includes the financial statements for the year ended 31 December 2024, reappointment of PKF Littlejohn as auditors, authorization to determine the auditors’ remuneration, re-election of Cedric Simonet and a proposal to approve share buybacks. Shareholders may appoint representatives; proxies must be submitted to Computershare Investor Services by 5 September 2025. The next audited financial statements will cover the period to 31 December 2025 and will be presented at the 2026 AGM. » Altro su de.investing.com
Kensington Trust Singapore reduces stake in Bluebird Mining Ventures below 5%

Kensington Trust Singapore Limited has reduced its stake in Bluebird Mining Ventures Ltd from 9.993% to 4.885%, falling below the reportable threshold of 5%. The reduction includes both directly held shares and financial instruments such as warrants. Bluebird Mining Ventures emphasizes its compliance with UK transparency guidelines and market abuse regulations. » Altro su de.investing.com
Bluebird Mining Ventures: major shareholders increase stake to 18.79%

Major shareholders RS & CA Jennings & Catalyse Capital Ltd have increased their stake in Bluebird Mining Ventures Ltd from 12.56% to 18.79%. The increase includes both direct voting rights and financial instruments such as spread-betting positions and warrants. Bluebird Mining Ventures reported the crossing of the notification threshold in accordance with UK disclosure rules. » Altro su de.investing.com

Dividendi storici Dividendi

Tutte le metriche sui dividendi Tutte le metriche

Nel 2021, Bluebird Bio ha già distribuito 7,69€ di dividendi. L'ultimo pagamento è avvenuto a novembre 2021.

Dati finanziari dell'azienda

Nell'ultimo trimestre, Bluebird Bio ha registrato ricavi pari a 35.78m€ e un utile netto di −26.87m€

(EUR)	mar 2025	YoY
Ricavi	+35.78m	-
Utile lordo	+24.47m	-
Utile netto	−26.87m	-
EBITDA	−7.10m	-

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	+41.76m€
Numero di azioni	9.79m
Massimo/minimo a 52 settimane	+24,54€ - +2,75€
Dividendi	No
Beta	0,37
Rapporto P/E	−0,20
Rapporto PEG	0,00
Rapporto P/B	−1,53
Rapporto P/S	+0,58

Profilo aziendale

bluebird bio, Inc. ist ein Biotechnologieunternehmen, das innovative Gentherapien für schwere genetische Krankheiten erforscht, entwickelt und vermarktet. Zu den Produktkandidaten des Unternehmens für schwere genetische Erkrankungen gehören Betibeglogene Autotemcel zur Behandlung der transfusionsabhängigen ß-Thalassämie, Lovotibeglogene Autotemcel zur Behandlung der Sichelzellkrankheit (SCD) und Elivaldogene Autotemcel zur Behandlung der zerebralen Adrenoleukodystrophie. Das klinische Studienprogramm des Unternehmens umfasst HGB-205, HGB-206 und HGB-210 zur Untersuchung der Sicherheit und Wirksamkeit von lovo-cel bei der Behandlung von Patienten mit SCD sowie HGB-204, HGB-205, HGB-207 und HGB-212 zur Untersuchung der Sicherheit und Wirksamkeit von beti-cel bei der Behandlung von Patienten mit ß-Thalassämie. Es hat strategische Kooperations- und Lizenzvereinbarungen mit Orchard Therapeutics Limited, Forty Seven, Inc. und Magenta Therapeutics, Inc. Das Unternehmen war früher unter dem Namen Genetix Pharmaceuticals, Inc. bekannt und änderte im September 2010 seinen Namen in bluebird bio, Inc. bluebird bio, Inc. wurde 1992 gegründet und hat seinen Hauptsitz in Cambridge, Massachusetts.

Nome	Bluebird Bio
CEO	Andrew Obenshain
Sede centrale	Cambridge, ma Stati Uniti
Sito web	bluebirdbio.com
Settore	Sanità
Industria	Biotecnologia
Quotazione in borsa	19/06/2013
Dipendenti	248